Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 5/20 | 0.38 |
| ▸ | ALPL | P05186 | 3/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622940 | 0.86 | GPR3 (0.41) | GPR3CHRM5KIF11NPC1RAB9A | |
| SCHEMBL1066850 | 0.85 | NPC1 (0.35) | CHRM5NPC1RAB9A | |
| SCHEMBL8124892 | 0.85 | CHRM5 (0.38) | GPR3CHRM5RUNX1NPC1RAB9A | |
| SCHEMBL7420861 | 0.83 | KIF11 (0.34) | KIF11 | |
| SCHEMBL15352618 | 0.81 | L3MBTL1 (0.40) | GPR3PDE2ALMNA | |
| SCHEMBL15352801 | 0.81 | PDE2A (0.35) | GPR3KIF11CES1PDE2ASLC6A2 | |
| SCHEMBL1068998 | 0.80 | GPR3 (0.37) | GPR3KIF11NPC1RAB9ACES1 | |
| SCHEMBL77754 | 0.80 | CA1 (0.39) | CES1CYP1A2CYP3A4GAABLM | |
| SCHEMBL1068538 | 0.78 | POLB (0.36) | NPC1RAB9ALMNAPKMALOX15 | |
| SCHEMBL17046284 | 0.77 | ALDH1A1 (0.41) | GPR3RAB9AUSP2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | claimed |
| EP-3625222-B1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-21 | — | — | EP | claimed |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-06-11 | — | — | US | claimed |
| EP-3625222-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | claimed |
| CN-110612296-A | Phenyl derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | claimed |
| WO-2018210994-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | claimed |
| US-20150011559-A1 | ANTIMICROBIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | claimed |
| WO-2013106761-A2 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-07-18 | — | — | WO | claimed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | claimed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | claimed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | claimed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | claimed |
| EP-1194417-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AG (DE) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078733-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | claimed |
| CN-113272285-B | Oxadiazole-containing compound and pharmaceutical composition containing same | 爱思开生物制药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| EP-3625222-B1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-21 | — | — | EP | disclosed |
| WO-2002096421-A1 | 5-SUBSTITUTED-2-ARYLPYRIDINES AS CRF1 MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1194417-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AG (DE) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078733-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | GPR3 59/4885ALPL 4846/4885CHRM5 723/4885 |
| US-20150011559-A1 | ANTIMICROBIAL AGENTS | CFTR, MPO, ATF1 | GPR3 4804/4885ALPL 1470/4885CHRM5 4706/4885 |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | GPR3 3876/4885ALPL 229/4885CHRM5 1918/4885 |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | GPR3 58/4885ALPL 4842/4885CHRM5 764/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | GPR3 4181/4885ALPL 160/4885CHRM5 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.